Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs-Reference-Cited by-同舟云学术

Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modifying Antirheumatic Drugs

Published:2016-03 Issue:3 Volume:22 Page:209-218
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Harnett James¹,Wiederkehr Daniel²,Gerber Robert³,Gruben David⁴,Bourret Jeffrey⁵,Koenig Andrew⁵

Affiliation:

1. Senior Director, Real World Data and Analytics, Worldwide Policy, Pfizer, New York, New York.

2. Director, Worldwide Policy, Pfizer, New York, New York.

3. Senior Director, Outcomes and Evidence, Statistics, Pfizer, Groton, Connecticut.

4. Senior Director, Statistics, Pfizer, Groton, Connecticut.

5. Senior Director, North America Medical Affairs, Pfizer, Collegeville, Pennsylvania.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost of treating rheumatoid arthritis in the primary care public health system in Ireland: A time-driven activity-based cost analysis;Exploratory Research in Clinical and Social Pharmacy;2024-06

2. Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance;Journal of Managed Care & Specialty Pharmacy;2024-05

3. Real-world experience with filgotinib for rheumatoid arthritis in Germany;Zeitschrift für Rheumatologie;2024-04-30

4. Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry;The Journal of Rheumatology;2024-02-15

5. Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study;Rheumatology;2024-02-15